Inhibikase Therapeutics 2022 Annual Meeting results: share count increase fails

Inhibikase Therapeutics, Inc.

Directors Roy Freeman and Paul Grint elected with ~11.4M and ~11.5M votes for; ~4.5M broker non-votes.
Ratification of CohnReznick LLP as auditor approved: 16.4M for, 31.5K against, 56.6K abstain.
Proposal to increase authorized shares from 100M to 200M failed: 15M for, 1.4M against, not meeting required percentage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.